UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

British journal of dermatology (1951), 2012-09, Vol.167 (3), p.668-677

2012

Volltextzugriff (PDF)

Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review

British Journal of Dermatology, 2007-10, Vol.157 (4), p.649-655

2007

Volltextzugriff (PDF)

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.949-961

2015

Volltextzugriff (PDF)

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

British journal of dermatology (1951), 2016-06, Vol.174 (6), p.1266-1276

2016

Volltextzugriff (PDF)

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

British journal of dermatology (1951), 2018-02, Vol.178 (2), p.e105-e107

2018

Volltextzugriff (PDF)

Treatment of two patients with generalized pustular psoriasis with the interleukin‐1β inhibitor gevokizumab

British journal of dermatology (1951), 2015-07, Vol.173 (1), p.239-241

2015

Volltextzugriff (PDF)

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

British journal of dermatology (1951), 2020-12, Vol.183 (6), p.1037-1048

2020

Volltextzugriff (PDF)

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Journal of the European Academy of Dermatology and Venereology, 2020-12, Vol.34 (12), p.2830-2838

2020

Volltextzugriff (PDF)

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Journal of the European Academy of Dermatology and Venereology, 2016-07, Vol.30 (7), p.1148-1158

2016

Volltextzugriff (PDF)

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

British journal of dermatology (1951), 2020-10, Vol.183 (4), p.664-672

2020

Volltextzugriff (PDF)

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.935-944

2021

Volltextzugriff (PDF)

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

British journal of dermatology (1951), 2019-07, Vol.181 (1), p.88-95

2019

Volltextzugriff (PDF)

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology, 2014-02, Vol.28 (2), p.192-203

2014

Volltextzugriff (PDF)

Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch

British journal of dermatology (1951), 2016-07, Vol.175 (1), p.19-20

2016

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

Journal of the American Academy of Dermatology, 2009-04, Vol.60 (4), p.643-659

2009

Volltextzugriff (PDF)

AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1304-1305

2021

Volltextzugriff (PDF)

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

British journal of dermatology (1951), 2014-07, Vol.171 (1), p.137-147

2014

Volltextzugriff (PDF)

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

British journal of dermatology (1951), 2018-10, Vol.179 (4), p.844-852

2018

Volltextzugriff (PDF)

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

Journal of the European Academy of Dermatology and Venereology, 2017-10, Vol.31 (10), p.1686-1692

2017

Volltextzugriff (PDF)

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

British journal of dermatology (1951), 2008-05, Vol.158 (5), p.1107-1116

2008

Volltextzugriff (PDF)

Quality of life instruments in psoriasis clinical trials

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.563-563

2017

Volltextzugriff (PDF)

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Annals of oncology, 2015-09, Vol.26 (9), p.1923-1929

2015

Volltextzugriff (PDF)

Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab

Clinical and experimental dermatology, 2016-04, Vol.41 (3), p.324-326

2016

Volltextzugriff (PDF)

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

British journal of dermatology (1951), 2013-11, Vol.169 (5), p.992-999

2013

Volltextzugriff (PDF)

Palmoplantar pustular psoriasis unresponsive to the interleukin-1[beta] antagonist canakinumab

Clinical and experimental dermatology, 2016-04, Vol.41 (3), p.324

2016

Volltextzugriff (PDF)

1 – 25 von 2.264

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.387)
Mit Volltextzugriff
(1.806)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis

Treatment of two patients with generalized pustular psoriasis with the interleukin‐1β inhibitor gevokizumab

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

Quality of life instruments in psoriasis clinical trials

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

Palmoplantar pustular psoriasis unresponsive to the interleukin-1[beta] antagonist canakinumab

Suchergebnisse filtern